Form 4: Pyxis Oncology Director, Thomas Civik, Acquires Stock Options

Thomas Civik, a director at Pyxis Oncology, acquired stock options for 36,979 shares at an exercise price of $0.98 on March 31, 2025.

Summary

• On March 31, 2025, Thomas Civik, a director of Pyxis Oncology, Inc., acquired stock options for 36,979 shares.
• The exercise price for these options is $0.98 per share.
• The options vest 100% on the first anniversary of the grant date, contingent upon continued service.
• Following the transaction, Civik directly owns derivative securities for 36,979 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director. While it could indicate confidence, it's not definitively positive or negative.

Positives

• The acquisition of stock options by a director may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the transactions of company directors and officers, which can be informative for investors.

Stakeholder Impact

• The acquisition of stock options by a director can influence investor sentiment.

Key Dates

Keywords

Stock Options, Form 4, Director, Beneficial Ownership, Pyxis Oncology, PYXS, Civik, Acquisition